儿童医院血培养阳性直接快速表型药敏试验的性能与临床影响评估
该研究在儿科医院回顾性比较82例常规药敏试验与80例干预后使用Accelerate Pheno Blood Culture panel的病例。Pheno与肉汤微量稀释法分类一致率为91.5%,药敏报告中位时间从20.0小时降至9.7小时,治疗调整时间从36.0小时降至25.0小时,美罗培南中位使用时长从64.8小时降至31.6小时,住院时长和30天死亡率无变化。
要点
- Pheno直接血培养药敏与参考方法分类一致率91.5%,极重大误差0.1%。
- 药敏报告中位时间由20.0小时缩短至9.7小时,治疗调整时间由36.0小时缩短至25.0小时。
- 美罗培南中位使用时长由64.8小时降至31.6小时,住院时长与30天死亡率无变化。
核心结论
- Pheno在儿童中性能准确,实施后可加快药敏报告、缩短至优化治疗时间并减少美罗培南使用时长。
研究设计与样本
- 回顾性比较儿童医院血培养阳性且为面板覆盖革兰阴性菌的两组队列:常规药敏法82例与Pheno干预后80例。
主要发现
- Pheno药敏与肉汤微量稀释参考法分类一致率91.5%,轻微误差7.4%、重大误差1.1%、极重大误差0.1%。
- 血培养阳性至药敏报告中位时间从20.0小时降至9.7小时(P < 0.001)。
- 血培养阳性至治疗调整中位时间从36.0小时降至25.0小时(P < 0.001)。
- 美罗培南中位使用时长从64.8小时降至31.6小时(P = 0.04)。
- 住院时长或30天死亡率未见变化。
关键数值与推荐
- 分类一致率91.5%,轻微误差7.4%,重大误差1.1%,极重大误差0.1%。
- 药敏报告中位时间20.0小时 vs 9.7小时(P < 0.001)。
- 治疗调整中位时间36.0小时 vs 25.0小时(P < 0.001)。
- 美罗培南中位使用时长64.8小时 vs 31.6小时(P = 0.04)。
临床怎么用
- 对面板覆盖的革兰阴性菌血培养阳性标本,可直接用Pheno快速获得表型药敏以缩短报告时间。
- 快速药敏结果可用于更早调整抗菌治疗并缩短美罗培南使用时长。
局限性
- 研究为单中心儿科医院回顾性队列比较。
- 仅评估面板覆盖的革兰阴性菌,未涉及其他病原体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bloodstream infection poses a significant medical emergency that necessitates timely administration of appropriate antibiotics. Standard laboratory workup for antimicrobial susceptibility testing (AST) involves subculture of organisms from positive blood bottles followed by testing using broth microdilution; however, this process can take several days. The Accelerate Pheno Blood Culture panel (Pheno) provides rapid phenotypic testing of selected Gram-negative organisms directly from positive blood cultures. This has the potential to shorten the AST process to several hours and impact time to antimicrobial optimization and subsequent clinical outcomes; however, these metrics have not been assessed in pediatric populations. We retrospectively compared two patient cohorts with blood cultures positive for on-panel Gram-negative organisms: 82 cases tested by conventional AST methods, and 80 cases postintervention at our pediatric hospital. Susceptibility testing from the Pheno yielded 91.5% categorical agreement with a broth microdilution-based reference method with 7.4% minor error, 1.1% major error, and 0.1% very major error rates. The median time from blood culture positivity to AST decreased from 20.0 h to 9.7 h (P < 0.001), leading to an overall decrease in time from blood culture positivity to change in therapy from 36.0 h to 25.0 h (P < 0.001). There was no observed change in length of stay or 30-day mortality. Median duration on meropenem decreased from 64.8 h to 31.6 h (P = 0.04). We conclude the Pheno had accurate performance and that implementation allowed for faster AST reporting, improved time to optimal therapy, and decreased duration on meropenem in children.
引用
- Truong TT, Mongkolrattanothai K, Flores II, et al. Evaluation of the Performance and Clinical Impact of a Rapid Phenotypic Susceptibility Testing Method Directly from Positive Blood Culture at a Pediatric Hospital. J Clin Microbiol. 2022. PMID: 35852363. doi:10.1128/jcm.00122-22
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。